AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17296533 — intervention group
Group type: EXPERIMENTAL
Intervention: Steatosis scores among diabetic patients
Number of subjects: 1143
Study 15131684 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser biometry
Number of subjects: 39
Study 15131684 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound biometry
Number of subjects: 39
Study 11413739 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (1.12 mg/day) nasal spray administered twice daily
Number of subjects: 180
Study 11413739 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine (0.4 mg/day) nasal spray administered twice daily
Number of subjects: 180
Study 11413739 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 180
Study 11413739 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine
Number of subjects: 180
Study 11413739 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine and Levocabastine
Number of subjects: 180
Study 9438892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution combined with induced hypotension (Group 1)
Number of subjects: 16
Study 9438892 — intervention group
Group type: COMPARATOR
Intervention: Standard management of blood volume and pressure (Group 2)
Number of subjects: 16
Study 8273195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser therapy
Number of subjects: 40
Study 8273195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3121335 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 91
Study 3121335 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 91
Study 3121335 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 91
Study 31714844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day invitation period
Number of subjects: 201
Study 31714844 — intervention group
Group type: COMPARATOR
Intervention: 3-day invitation period
Number of subjects: 201
Study 30575346 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopheresis with standard immunosuppression therapy (tacrolimus, mycophenolate, prednisone) for 10-15 sessions during the first 6 months after transplantation.
Number of subjects: 60
Study 30575346 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppression therapy (tacrolimus, mycophenolate, prednisone) without photopheresis.
Number of subjects: 60
Study 27267951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 95
Study 27267951 — intervention group
Group type: COMPARATOR
Intervention: Sham negative ion generator (placebo)
Number of subjects: 95
Study 25671664 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous profile
Number of subjects: 351
Study 25671664 — intervention group
Group type: COMPARATOR
Intervention: Mestizo profile
Number of subjects: 351
Study 23926253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (selective D2/D3 agonist)
Number of subjects: 0
Study 23926253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20622414 — intervention group
Group type: EXPERIMENTAL
Intervention: Various tobacco cessation interventions (specific details not provided)
Number of subjects: 646
Study 20622414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (Arm 4)
Number of subjects: 646
Study 20622414 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and behavioral therapy (not specified if part of the intervention arms)
Number of subjects: 646
Study 19301517 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/fluoride dentifrice (0.3% triclosan/2.0% PVM/MA copolymer/0.243% sodium fluoride in a 17% dual silica base)
Number of subjects: 81
Study 19301517 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 81
Study 16467064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sixteen‐multidetector row computed tomography (MDCT)
Number of subjects: 50
Study 16467064 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 50
Study 14763194 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinacrine pellets (252 mg total, 36 mg per pellet, three applications)
Number of subjects: 180
Study 10944481 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (VA) intervention - 16,700 IU weekly
Number of subjects: 293
Study 10944481 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (VA) intervention - 200,000 IU
Number of subjects: 293
Study 10944481 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (VA) on admission (31 infants)
Number of subjects: 293
Study 10944481 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (VA) on discharge (32 infants)
Number of subjects: 293
Study 10944481 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 293
Study 9501691 — intervention group
Group type: EXPERIMENTAL
Intervention: MNA + MA
Number of subjects: 155
Study 9501691 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA) and Adrenaline (A)
Number of subjects: 155
Study 9501691 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanillylmandelic acid (VMA)
Number of subjects: 155
Study 9501691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA)
Number of subjects: 155
Study 9501691 — intervention group
Group type: EXPERIMENTAL
Intervention: DOPA
Number of subjects: 155
Study 8117509 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosynthesis (DHS)
Number of subjects: 43
Study 8117509 — intervention group
Group type: COMPARATOR
Intervention: Primary hemiarthroplasty (HA)
Number of subjects: 43
Study 2940938 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.82 mg/kg) plus Ketamine (2.0 mg/kg i.m.)
Number of subjects: 69
Study 2940938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (not specified dosage) plus Ketamine (2.0 mg/kg i.m.)
Number of subjects: 69
Study 2940938 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (2.4 mg/kg i.m. alone)
Number of subjects: 69
Study 31558380 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including educational in-service, evidence-based tools for assessing neuropsychiatric symptoms, and monthly interprofessional team meetings
Number of subjects: 10
Study 31558380 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 10
Study 30589048 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated chemotherapy (CC group) with cisplatin at 80 mg/m2 from 10:00 to 22:00 and 5-fluorouracil (5-FU) at 1000 mg/m2 plus citrovorum factor at 200 mg/m2 from 22:00 to 10:00 for 3 days.
Number of subjects: 60
Study 30589048 — intervention group
Group type: COMPARATOR
Intervention: Routine chemotherapy (RC group) with cisplatin infusion within 1 h and 5-FU infusion for about 24 h, same dosage as CC group.
Number of subjects: 60
Study 30589048 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated chemotherapy (CC group)
Number of subjects: 60
Study 30589048 — intervention group
Group type: COMPARATOR
Intervention: Routine chemotherapy (RC group)
Number of subjects: 60
Study 30589048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 27861157 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-B (pentostatin, cyclophosphamide, rituximab with bevacizumab)
Number of subjects: 65
Study 25161021 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1000mg, 30-minute infusion
Number of subjects: 10
Study 25161021 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500mg, 3-hour infusion
Number of subjects: 10
Study 22403209 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrating a physical activity counselor (PAC) into primary health care teams
Number of subjects: 120
Study 20345421 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anaesthesia with target-controlled remifentanil
Number of subjects: 30
Study 20345421 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal anaesthesia with target-controlled remifentanil
Number of subjects: 30
Study 18759607 — intervention group
Group type: EXPERIMENTAL
Intervention: Codman Hakim regular
Number of subjects: 0
Study 18759607 — intervention group
Group type: EXPERIMENTAL
Intervention: Miethke ProGAV
Number of subjects: 0
Study 18759607 — intervention group
Group type: EXPERIMENTAL
Intervention: Codman Hakim with SiphonGuard
Number of subjects: 0
Study 18759607 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Strata
Number of subjects: 0
Study 18759607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sophysa Sophy
Number of subjects: 0
Study 18759607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sophysa Polaris
Number of subjects: 0
Study 15904635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin at 10 mg
Number of subjects: 0
Study 15904635 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin, pravastatin, and simvastatin
Number of subjects: 0
Study 11689983 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR) group
Number of subjects: 51
Study 11689983 — intervention group
Group type: EXPERIMENTAL
Intervention: No Knowledge of Results (NKR) group
Number of subjects: 51
Study 11689983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 9728642 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (initially 20 mg, flexible dosing up to 50 mg/d)
Number of subjects: 187
Study 9728642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching-image placebo)
Number of subjects: 187
Study 8086867 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins
Number of subjects: 2045
Study 8086867 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2045
Study 2660973 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin-Erythromycin (N-E)
Number of subjects: 125
Study 2660973 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin-Metronidazole (E-M)
Number of subjects: 125
Study 8158888 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-restricted diet (0.4 g per kg)
Number of subjects: 0
Study 8158888 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition
Number of subjects: 0
Study 759617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.7 microgram/kg
Number of subjects: 5
Study 759617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.4 microgram/kg
Number of subjects: 5
Study 759617 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphaprodine 0.135 mg/kg
Number of subjects: 5
Study 759617 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphaprodine 0.270 mg/kg
Number of subjects: 5
Study 759617 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.564 mg/kg
Number of subjects: 5
Study 759617 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 1.127 mg/kg
Number of subjects: 5
Study 759617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 759617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 5
Study 759617 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphaprodine
Number of subjects: 5
Study 31304562 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Aware Parent (intervention)
Number of subjects: 355
Study 31304562 — intervention group
Group type: COMPARATOR
Intervention: Active control (online access to medically-accurate information on adolescent sexual health)
Number of subjects: 355
Study 28914251 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet‐rich fibrin (PRF)
Number of subjects: 50
Study 28914251 — intervention group
Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 50
Study 28914251 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 50
Study 26069259 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Intervention (II)
Number of subjects: 1193
Study 26069259 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Educational (EE)
Number of subjects: 1193
Study 26069259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (II and EE)
Number of subjects: 1193
Study 24511708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg day(‐1))
Number of subjects: 45
Study 24511708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU day(‐1))
Number of subjects: 45
Study 24511708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 21511150 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative counseling
Number of subjects: 851
Study 21483189 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tube removal at 200 ml/day (trial group)
Number of subjects: 138
Study 21483189 — intervention group
Group type: COMPARATOR
Intervention: Chest tube removal at 150 ml/day (control group)
Number of subjects: 138
Study 17524938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 2-hour postdose (C2) levels
Number of subjects: 215
Study 17524938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine trough (C0) levels
Number of subjects: 215
Study 15208500 — intervention group
Group type: EXPERIMENTAL
Intervention: GCPET
Number of subjects: 25
Study 15208500 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 25
Study 15208500 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 25
Study 11434169 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with glomerulonephritis
Number of subjects: 16
Study 11434169 — intervention group
Group type: COMPARATOR
Intervention: Control group (Wilm's tumour)
Number of subjects: 16
Study 9596205 — intervention group
Group type: EXPERIMENTAL
Intervention: DZP rectal gel (15 mg)
Number of subjects: 20
Study 9596205 — intervention group
Group type: COMPARATOR
Intervention: Intravenous DZP (7.5 mg)
Number of subjects: 20
Study 7850397 — intervention group
Group type: EXPERIMENTAL
Intervention: True electroconvulsive therapy (ECT)
Number of subjects: 30
Study 7850397 — intervention group
Group type: COMPARATOR
Intervention: Sham ECT
Number of subjects: 30
Study 3241216 — intervention group
Group type: EXPERIMENTAL
Intervention: 5HT (1 ng/kg per min)
Number of subjects: 7
Study 3241216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (500 ng/kg per min)
Number of subjects: 7
Study 3241216 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205‐930 (700 ng/kg per min)
Number of subjects: 7
Study 3241216 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (100 ng/kg per min)
Number of subjects: 7
Study 30898114 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based aftercare groups (6 sessions over 6 months)
Number of subjects: 206
Study 30898114 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based aftercare groups
Number of subjects: 206
Study 30898114 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 206
Study 29188900 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Training (ART) + fortified milk
Number of subjects: 56
Study 29188900 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) + fortified milk
Number of subjects: 56
Study 29188900 — intervention group
Group type: COMPARATOR
Intervention: Control (RT)
Number of subjects: 56
Study 25319146 — intervention group
Group type: EXPERIMENTAL
Intervention: Corner Osteotomy (CO)
Number of subjects: 30
Study 25319146 — intervention group
Group type: COMPARATOR
Intervention: Pedicle Subtraction Osteotomy (PSO)
Number of subjects: 30
Study 22972399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 18
Study 22972399 — intervention group
Group type: COMPARATOR
Intervention: Low-dose atorvastatin (10 mg)
Number of subjects: 18
Study 21262890 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting skills plus healthy lifestyle group (n = 85)
Number of subjects: 169
Study 21262890 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle-only group (n = 84)
Number of subjects: 169
Study 19223428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level muscle activity during the 1-h (18)F-FDG uptake phase
Number of subjects: 20
Study 19223428 — intervention group
Group type: COMPARATOR
Intervention: No low-level muscle activity (control group)
Number of subjects: 20
Study 16289241 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal adipose tissue levels of OC p,p'‐DDE
Number of subjects: 31
Study 16289241 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk levels of p,p'‐DDE, dieldrin, and HCB
Number of subjects: 31
Study 16289241 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue levels of OC metabolites
Number of subjects: 31
Study 14684710 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 134
Study 11571237 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT‐711 (210 mg)
Number of subjects: 93
Study 11571237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 9609905 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 41
Study 9609905 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 41
Study 8112194 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-management diet
Number of subjects: 70
Study 8112194 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate/fiber diet
Number of subjects: 70
Study 8112194 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-lipid diet
Number of subjects: 70
Study 2647022 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 56
Study 2647022 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 56
Study 2647022 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound, radioisotope, CT imaging, inspection and palpation at laparotomy
Number of subjects: 56
Study 2647022 — intervention group
Group type: COMPARATOR
Intervention: Imaging techniques (ultrasound, radioisotope, CT)
Number of subjects: 56
Study 31244367 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral formulas with high GI (Nutrienteral 1.5®, Novasource GI Control®, Diamax®, Isosource Soya®)
Number of subjects: 40
Study 31244367 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral formulas with intermediate GI (Fresubin 1.2 HP Fibre®, Nutrison Energy Multifiber 1.5®)
Number of subjects: 40
Study 31244367 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral formulas with low GI (Trophic 1.5®, Glucerna®, Novasource GC HP®)
Number of subjects: 40
Study 31045289 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency ventilation (LFV)
Number of subjects: 37
Study 31045289 — intervention group
Group type: COMPARATOR
Intervention: Both lungs left collapsed (control)
Number of subjects: 37
Study 28129714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil ODT
Number of subjects: 118
Study 25385203 — intervention group
Group type: EXPERIMENTAL
Intervention: Police-patrolled walking plus social marketing
Number of subjects: 434
Study 25385203 — intervention group
Group type: COMPARATOR
Intervention: Police-patrolled walking-only
Number of subjects: 434
Study 25385203 — intervention group
Group type: COMPARATOR
Intervention: No-walking intervention
Number of subjects: 434
Study 23998657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 190
Study 21410446 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of drugs added to a participant's medication regimen during the 1‐year study period
Number of subjects: 377
Study 21410446 — intervention group
Group type: COMPARATOR
Intervention: Geriatric conditions and functional status (IADL function, cognitive impairment, depression, visual impairment, incontinence, constipation, history of falls or gait instability)
Number of subjects: 377
Study 21410446 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 377
Study 19628217 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐cell receptor excision circles (TRECs) quantification using neonatal Guthrie cards
Number of subjects: 489
Study 17364230 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drinks (target blood alcohol level = .08%)
Number of subjects: 42
Study 17364230 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic drinks
Number of subjects: 42
Study 15377745 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 19
Study 15377745 — intervention group
Group type: EXPERIMENTAL
Intervention: Amesergide (AMSG)
Number of subjects: 19
Study 11794416 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 20
Study 11794416 — intervention group
Group type: COMPARATOR
Intervention: Reading attention control
Number of subjects: 20
Study 9322808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/d)
Number of subjects: 59
Study 9322808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8454796 — intervention group
Group type: EXPERIMENTAL
Intervention: Solidified benzyl benzoate and tenside agents (A)
Number of subjects: 23
Study 8454796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23
Study 3961072 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group, drinking .08 ml of pure alcohol per kg body weight
Number of subjects: 40
Study 3961072 — intervention group
Group type: COMPARATOR
Intervention: Placebo group, drinking only tonic
Number of subjects: 40
Study 28805094 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance task-specific training
Number of subjects: 52
Study 28805094 — intervention group
Group type: COMPARATOR
Intervention: General physiotherapy (control)
Number of subjects: 52
Study 27090275 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgi shield (8% carboxymethyl chitosan)
Number of subjects: 33
Study 27090275 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 33
Study 25115420 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HYS)
Number of subjects: 264
Study 25115420 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringers (LAR)
Number of subjects: 264
Study 22254230 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 10
Study 22254230 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) + enamel matrix derivative (EMD)
Number of subjects: 10